FDA Approves First Immunotherapy Regimen for Breast Cancer

Home Blog FDA Approves First Immunotherapy Regimen for Breast Cancer

The Food and Drug Administration granted its first approval to an immunotherapy regimen for breast cancer on March 8, 2019. This decision comes after an October study from the New England Journal of Medicine found that therapy extended progression-free survival of triple-negative breast cancer. Progression-free survival with the treatment was on average 7.4 months, compared to 4.8 months with the placebo. 

This new treatment is the first time immunotherapy has worked in this type of breast cancer and is a huge step forward. The final report with additional findings.is expected in September 2020 from the drugmaker, Genetech. 

Read the complete story from CNN

0 comments

Back to Top